Expression of Human Epidermal Growth Factor Receptor 2 in Meningiomas

Abstract

Background: Meningiomas consist of 15%–30% of the primary intracranial tumors, and high-grade meningiomas have a higher recurrence after surgery. The human epidermal growth factor receptor 2 (HER2) status is important in the medical management of patients with various human cancers. This study aimed to evaluate HER2 expression in meningiomas and the correlation between this expression and age, gender, and grade. Materials and Methods: In a descriptive-analytic study, immunohistochemistry (IHC) with HER2 marker was done on confirmed cases of meningioma which were referred to the pathology laboratory from 2008 to 2015. The primary antihuman antibody against c-erbB-2 oncoprotein (DAKO Diagnostics) was used for IHC. Results: Of 117 patients, 68.4% were males. The mean age of the patients was 53.6 years. Grades I, II, and III tumors were 90.6%, 8.5%, and 0.9% of cases, respectively. Totally, 76 (65%) of patients were HER2 positive, with only 7.7% of highly expressed HER2. There was no significant correlation between the mean age (P = 0.672), age group (P = 0.256), sex (P = 0.574), and grade (P = 0.093) and HER2 expression status. Conclusions: We did not find a statistically significant correlation between age, sex, or grade and HER2 status; however, further studies with a higher number of Grades II and III meningiomas and using the fluorescent in situ hybridization in equivocal cases may be of benefit in this way.

Keywords

Human epidermal growth factor receptor 2 - immunohistochemistry - meningioma

• References

• 1 Mahzouni P, Movahedipour M. An immunohistochemical study of HER2 expression in meningioma and its correlation with tumor grade. Pathol Res Pract 2012; 208: 221-4
• 2 Apra C, Peyre M, Kalamarides M. Current treatment options for meningioma. Expert Rev Neurother 2018; 18: 241-9
• 3 Perry A, Louis DN, Scheithauer BW, Budka H, Deimling VA. Meningiomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. editors World Health Organization Classification of the Central Nervous System. Lyon: IARC; 2007: 164-72
• 4 Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y. et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 2013; 15 (02) ii1-56
• 5 Thuijs NB, Uitdehaag BM, Van Ouwerkerk WJ, van der Valk P, Vandertop WP, Peerdeman SM. Pediatric meningiomas in the Netherlands 1974-2010: A descriptive epidemiological case study. Childs Nerv Syst 2012; 28: 1009-15
• 6 Wang S, Liu X, Wang W, Tu Y, Wang C, Mei J. et al. The effects of silencing the her2 gene on proliferation and angiogenesis of meningioma cellsin vivo and in vitro. Ann Clin Lab Sci 2018; 48: 580-6
• 7 Telugu RB, Chowhan AK, Rukmangadha N, Patnayak R, Phaneendra BV, Prasad BC. et al. Human epidermal growth factor receptor 2/neu protein expression in meningiomas: An immunohistochemical study. J Neurosci Rural Pract 2016; 7: 526-31
• 8 Arnli MB, Winther TL, Lydersen S, Torp SH. Prognostic value of ErbB2/HER2 in human meningiomas. PLoS One 2018; 13: e0205846
• 9 Olsen RJ, Lydiatt WM, Koepsell SA, Lydiatt D, Johansson SL, Naumann S. et al. C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck. Head Neck 2005; 27: 883-92
• 10 Potti A, Panwalkar A, Langness E, Sholes K, Tendulkar K, Chittajalu S. et al. Role of her-2/neu overexpression and clinical features at presentation as predictive factors in meningiomas. Am J Clin Oncol 2004; 27: 452-6
• 11 Abdelzaher E, El-Gendi SM, Yehya A, Gowil AG. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression. Br J Neurosurg 2011; 25: 707-13
• 12 Wang W, Tu Y, Wang S, Xu S, Xu L, Xiong Y. et al. Role of HER-2 activity in the regulation of malignant meningioma cell proliferation and motility. Mol Med Rep 2015; 12: 3575-82
• 13 Wickremesekera A, Hovens CM, Kaye AH. Expression of ErbB-1 and ErbB-2 in meningioma. J Clin Neurosci 2010; 17: 1155-8
• 14 Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E. et al. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. Glia 2012; 60: 1721-33
• 15 Loussouarn D, Brunon J, Avet-Loiseau H, Campone M, Mosnier JF. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study. Hum Pathol 2006; 37: 415-21
• 16 Andersson U, Guo D, Malmer B, Bergenheim AT, Brännström T, Hedman H. et al. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 2004; 108: 135-42
• 17 Waage IS, Vreim I, Torp SH. C-erbB2/HER2 in human gliomas, medulloblastomas, and meningiomas: A minireview. Int J Surg Pathol 2013; 21: 573-82
• 18 Laurendeau I, Ferrer M, Garrido D, D’Haene N, Ciavarelli P, Basso A. et al. Gene expression profiling of ErbB receptors and ligands in human meningiomas. Cancer Invest 2009; 27: 691-8
• 19 Wang CL, Mei JH, Wang SS, Xu S, Xu LL, Xiong YF. Expression of HER2/neu in meningiomas: An immunohistochemistry and fluorescence in situ hybridization study. Zhonghua Bing Li Xue Za Zhi 2010; 39: 156-60
• 20 Durand A, Champier J, Jouvet A, Labrousse F, Honnorat J, Guyotat J. et al. Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clin Neuropathol 2008; 27: 334-45
• 21 Ongaratti BR, Silva CB, Trott G, Haag T, Leães CG, Ferreira NP. et al. Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence. Braz J Med Biol Res 2016; 49: e5125